ASX Health Stocks: Imugene up on PD1-Vaxx cancer study expansion plans
Health & Biotech
Health & Biotech
Link copied to
Leader of the ASX health stocks today is Imugene (ASX:IMU) up 4.11% after announcing plans to present its PD1-Vaxx cancer checkpoint immunotherapy program at the ESMO Congress 2021 Annual Meeting in Paris.
The company says clinical results continue to indicate that PD1-Vaxx is showing early signs of immune responses in patients, with the development of antibodies to the drug target, PD-1.
Imugene is planning to expand the study to combine PD1-Vaxx with standard of care (SOC) therapy in the same lung cancer patient population.
This could include a PD-L1 inhibitor or another immunotherapy agent.
And inclusion criteria will allow patients that have either progressed on their previous therapy or did not have a response to their SOC and are at high risk of progression to enter the study.
PD1-Vaxx is also being evaluated for other tumour indications beyond non-small cell lung cancer (NSCLC).
Other ASX health stocks with news out today
Creso was up today after announcing it has increased its European market presence following the launch of a new e-commerce channel and marketing campaign.
The e-commerce channel will host the company’s cannaDOL range, which will be classified under new sub brand, ‘Born to move’ which includes:
Initially the platform will target Swiss consumers as the country presents a large addressable market – with annual per capita expenditure totalling CHF$2,500 (around AU$3696) in the country’s CHF$21 billion (around AU$31 billion) market for sports related activities.
Creso has also secured a maiden purchase order its animal health product through Polish company Polvet valued at CHF$54,120 (around A$80,141).
The cold cathode x-ray technology company was up 1.69% after announcing it had appointed well known radiology industry leader, Charlie Hicks, as the new head of its Mobile DR business.
Hicks was previously business director of Global X- Ray Solutions with Carestream Health and will drive commercial expansion in the US.
“Charlie understands practically every nuance of the global radiology business and is incredibly well networked,” Micro-X managing director Peter Rowland said.
“Under his strong and focused commercial leadership, we will build a world class network of direct sales and distributor relationships to capture a dominant market share for Micro-X’s DR products.”
The company’s share price dipped -2.89% today despite news of an agreement with Global Cancer Technology (GCT) to develop nanocrystals for treating breast cancer.
Essentially the scintillating nanocrystals (comprised of nontoxic minerals and rare earth elements) emit photons (light) when activated by a low dose of gamma radiation.
They have the potential to release a more localise and effective drug payload to treat cancers because x-rays can penetrate deep tissue.
Under the terms of the agreement, Imagion will be paid for certain R&D services while gaining an ownership interest in the arising GCT nanoscintillator product.